News Center
The information in the press releases on these pages was factually accurate on the date of publication. These press releases remain on AbbVie's website for historical purposes only. AbbVie assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information in these pages as current or accurate after their publication dates.
-
EPKINLY® receives Health Canada Approval for Adults with Follicular Lymphoma
-
UBRELVY® (ubrogepant) Recommended for Reimbursement by Canada's Drug Agency (CDA-AMC) for Acute Migraine Treatment
-
Abbvie statement ovarian cancer
-
AbbVie in Canada Appoints Tanu Misra as Vice President and General Manager
-
SKYRIZI® (risankizumab) Secures Listing on Ontario and Alberta Formularies in Ulcerative Colitis
-
RINVOQ® (upadacitinib) Demonstrated Superiority Versus HUMIRA® (adalimumab) for Primary Endpoint in a Head-to-Head Study in Rheumatoid Arthritis Patients Who Have Failed First TNF inhibitor
-
AbbVie and BioLabs Team Up to Support Life Sciences Innovation in Canada
-
MAVIRET® receives Health Canada Approval for the Treatment of Acute Hepatitis C Virus
-
SKYRIZI® (risankizumab) receives positive reimbursement recommendation by Canada’s Drug Agency for ulcerative colitis and AbbVie concludes letter of intent with the pan-Canadian Pharmaceutical Alliance
-
AbbVie and adMare BioInnovations Foster Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award in Quebec
-
LUPRON DEPOT® new strength receives Health Canada Approval for the Treatment of Advanced Prostate Cancer
-
ELAHERE® Receives Positive Reimbursement Recommendation by Canada's Drug Agency for Certain Types of Platinum-Resistant Ovarian Cancers
-
QULIPTA® (atogepant) Now Publicly Reimbursed in Quebec for Chronic Migraine and CGRP Class Review Published
-
AbbVie’s VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
-
Health Canada Approves ELAHERE® for Certain Types of PlatinumResistant Ovarian Cancers
-
RINVOQ® (upadacitinib) Receives Health Canada Notice of Compliance (NOC) for Giant Cell Arteritis in adults
-
AbbVie and U of T Mississauga’s SpinUp Announce Neuropeutics Inc as First AbbVie Biotech Innovators Award Recipient
-
SKYRIZI® (risankizumab) Now Available for Moderately to Severely Active Ulcerative Colitis, Expanding AbbVie's Portfolio Across Inflammatory Bowel Disease
-
AbbVie’s atogepant and onabotulinumtoxinA receive strong recommendations in the newly updated Canadian Headache Society (CHS) Migraine Prevention Guideline
-
AbbVie biotech innovators award press release
-
AbbVie and SpinUp Foster Canadian Life Sciences Innovation with the Launch of the AbbVie Biotech Innovators Award
-
Health Canada Approves AbbVie’s CONSTELLA® (linaclotide) for the Treatment of Functional Constipation in Pediatric Patients 6 to 17 Years of Age
-
AbbVie’s VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for the Treatment of Schizophrenia
-
AbbVie’s EPKINLYTM Receives First-Ever Time-Limited Reimbursement Recommendation by Canada’s Drug Agency
-
Approximately half of patients living with inflammatory bowel disease (IBD) have suboptimally controlled disease, according to data from new Canadian study
-
QULIPTA™ (atogepant) Now Approved by Health Canada for the Preventive Treatment of Chronic Migraine in Adults
-
AbbVie’s VYALEV™ (foslevodopa/foscarbidopa solution) Available for the Treatment of Advanced Parkinson’s Disease in Canada
At AbbVie in Canada, we acknowledge that we live and work on the traditional territories of many First Nations, Inuit and Métis Peoples. We would like to show respect to those Peoples who are the original and ongoing stewards of this land we call our home. We are grateful to collaborate on these traditional lands and humbled by the work that we do to enhance people’s lives in our communities.
Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade name, or trade dress in this site may be made without the prior written authorization of AbbVie Inc., except to identify the product or services of the company.
Copyright® 2026 AbbVie Corporation. Canada..